ReviewJHEP reports : innovation in hepatology2024
Cardiomyopathy in cirrhosis: From pathophysiology to clinical care.
Review in JHEP reports : innovation in hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 55 citations in OpenAlex.
- Post-transplant atrial tachyarrhythmias: Epidemiology, mechanisms, outcomes, and management across solid organs.World journal of transplantation · 2026Review
- Predictors of In-Hospital Mortality and Incomplete Kidney Recovery in Patients with Cirrhosis-Associated Non-Hepatorenal Syndrome Acute Kidney Injury: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Biventricular Systolic Function and Myocardial Deformation in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Speckle-Tracking Echocardiography and Cardiac Magnetic Resonance Feature Tracking Studies.Journal of clinical medicine · 2026Review
- Decoding the mechanistic basis of liver-muscle communication in health and disease.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Cirrhotic cardiomyopathy in children with biliary atresia and genetic intrahepatic cholestasis: clinical course and outcomes.Hepatology international · 2026Observational
- Cirrhotic cardiomyopathy: pathophysiology, assessment, and implications for liver transplantation.Therapeutic advances in gastroenterology · 2026Review
- First-phase ejection fraction for evaluating early left ventricular systolic function in patients with cirrhosis.The Journal of international medical research · 2026Article
- Association of NT-proBNP and sST2 with Diastolic Dysfunction in Cirrhotic Patients and Its Therapeutic Implications.International journal of molecular sciences · 2025Article
- Novel insights into cardiac structure, function, perfusion, and tissue characteristics in liver cirrhosis: a magnetic resonance analysis.European radiology · 2025Article
- Clinical Management of Patients with Heart Failure-2nd Edition.Journal of clinical medicine · 2025Article
- Alcoholic Liver Disease and Systemic Inflammatory Response Syndrome: Mortality Prediction Using Biomarkers and Clinical Scores.Journal of clinical medicine · 2025Article
- EASL postgraduate course report: Vascular biology in chronic liver disease and clinical management implications.JHEP reports : innovation in hepatology · 2025Review
- Intrahepatic cholestasis of pregnancy.Nature reviews. Disease primers · 2025Review
- Apoptosis in Cardiac Conditions Including Cirrhotic Cardiomyopathy.International journal of molecular sciences · 2025Review
- The Cardiohepatic Axis in Cirrhosis.JACC. Basic to translational science · 2025Review
- Cardiac Remodeling and Arrhythmic Burden in Pre-Transplant Cirrhotic Patients: Pathophysiological Mechanisms and Management Strategies.Biomedicines · 2025Review
- Addition of a Loop Diuretic to Norepinephrine During Treatment of Hepatorenal Syndrome Type 1.Kidney international reports · 2025Article
- Advances in intrahepatic and extrahepatic vascular dysregulations in cirrhotic portal hypertension.Frontiers in medicine · 2025Review
- Joint Group and Multi Institutional Position Opinion: Cirrhotic Cardiomyopathy-From Fundamentals to Applied Tactics.Medicina (Kaunas, Lithuania) · 2024Review
- The Cardiomyocyte in Cirrhosis: Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy.Reviews in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cirrhotic cardiomyopathy (CCM) is defined as systolic or diastolic dysfunction in the absence of prior heart disease or another identifiable cause in patients with cirrhosis, in whom it is an important determinant of outcome. Its underlying pathogenic/pathophysiological mechanisms are rooted in two distinct pathways: 1) factors associated with portal hypertension, hyperdynamic circulation, gut bacterial/endotoxin translocation and the resultant inflammatory phenotype; 2) hepatocellular insufficiency with altered synthesis or metabolism of substances such as proteins, lipids, carbohydrates, bile acids and hormones. Different criteria have been proposed to diagnose CCM; the first in 2005 by the World Congress of Gastroenterology, and more recently in 2019 by the Cirrhotic Cardiomyopathy Consortium. These criteria mainly utilised echocardiographic evaluation, with the latter refining the evaluation of diastolic function and integrating global longitudinal strain into the evaluation of systolic function, an important addition since the haemodynamic changes that occur in advanced cirrhosis may lead to overestimation of systolic function by left ventricular ejection fraction. Advances in cardiac imaging, such as cardiac magnetic resonance imaging and the incorporation of an exercise challenge, may help further refine the diagnosis of CCM. Over recent years, CCM has been shown to contribute to increased mortality and morbidity after major interventions, such as liver transplantation and transjugular intrahepatic portosystemic shunt insertion, and to play a pathophysiologic role in the genesis of hepatorenal syndrome. In this review, we discuss the pathogenesis/pathophysiology of CCM, its clinical implications, and the role of cardiac imaging modalities including MRI. We also compare diagnostic criteria and review the potential diagnostic role of electrocardiographic QT prolongation. At present, no definitive medical therapy exists, but some promising potential treatment strategies for CCM are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.